Table Graph
      published meta-analysis   sensitivity analysis   studies

lopinavir/ritonavir in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsReis (Hydroxychloroquine) (TOGETHER), 2021 0.26 [0.01; 5.88] 0.26[0.01; 5.88]Reis (Hydroxychloroquine) (TOGETHER), 202110%441NAnot evaluable hospitalizationdetailed resultsReis (Hydroxychloroquine) (TOGETHER), 2021 0.76 [0.30; 1.90] 0.76[0.30; 1.90]Reis (Hydroxychloroquine) (TOGETHER), 202110%441NAnot evaluable viral clearance detailed resultsReis (Hydroxychloroquine) (TOGETHER), 2021 0.92 [0.82; 1.03] 0.92[0.82; 1.03]Reis (Hydroxychloroquine) (TOGETHER), 202110%380NAnot evaluable viral clearance by day 14detailed resultsReis (Hydroxychloroquine) (TOGETHER), 2021 0.92 [0.82; 1.03] 0.92[0.82; 1.03]Reis (Hydroxychloroquine) (TOGETHER), 202110%380NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-19 03:45 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 509 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons